As shown in S2 Table, the significant increased HCC early recurrence risk were observed in patients with the combinations of higher risk genotypes and higher serum AFP level advanced tumor stage, poor tumor differentiation, or no TACE treatment. This evidence concerns the gene AFP and hepatocellular carcinoma.